China approves Phase II/III trial of Accro's AC-201 for vitiligo

Sep 8, 2026 12:20 (47d ago)

Verifying

Fosun Pharma Industrial received NMPA approval to conduct an AC-201 vitiligo trial.
Phase II/III adaptive seamless-design trial is planned for mainland China once conditions are met.
AC-201 is an oral TYK2/JAK1 inhibitor being developed for immune-mediated inflammatory diseases.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.